The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had...
Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE)...
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
CAMBRIDGE, Mass. and NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision...
Masimo CO2, O3 and Sedline measurements are now available on Philips high acuity MX750 & MX850 IntelliVue monitors Philips patient...
MS Canada’s cycling fundraising event series is back this June featuring road bike tours across 12 Canadian communities, bringing people...
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- MS Canada, the country’s leading organization in multiple sclerosis (MS) research and advocacy...
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of...
BRISBANE, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing...
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or...
BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Day...
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on...
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., May 24,...
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part...
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN...
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific...
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key...
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
LEXINGTON, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on...